New Advances In Antibody-Drug Conjugate Development And Bio-Analytics To Be Presented By Catalent Biologics At Upcoming PEGS Conference




SOMERSET, N.J. – April 27, 2017 — Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that Dr. David Rabuka, Global Head of Research and Development, Chemical Biology, Catalent Biologics, will be presenting at the upcoming Protein And Antibody Engineering Summit (PEGS), to be held at the Seaport World Trade Center, Boston, Massachusetts, on May 1 – 5, 2017.

Dr. Rabuka’s presentation, on Wednesday May 3, at 12:25 p.m., is part of the ‘Antibody-Drug Conjugates I: New Targets, Payloads and Alternative Formats’ conference track, and is entitled “Latest Advances Developing ADCs using SMARTag® Technology.” In the presentation, Dr. Rabuka will examine the growth of antibody-drug conjugates (ADCs) in clinical trials and preclinical development following on from the successes of the ADC drugs Kadcyla™ and Adcetris™. He will discuss how innovations in conjugation chemistry and linker technologies suggest further opportunities in ADC development, and review pre-clinical studies using Catalent’s SMARTag technology platform, which enables precise, programmable, site-selective chemical protein modification.

In addition, Catalent Biologics’ analytical services will be showcasing expert posters on “The Use of LC-MS to Monitor Levels of Oxidation and Deamidation in Proteins for Release and Stability” by Anne Marie Rogan, Senior Associate Scientist and “Quantitation and Characterization of Polysorbate-80 by HPLC and Charged Aerosol Detection” by Luke Deters, Senior Manager, Large Molecule Analytical Chemistry.

Dr. Rabuka assumed the role of Catalent’s Global Head of R&D Chemical Biology in October 2014, following Catalent’s acquisition of Redwood Bioscience Inc., where he was President and Chief Scientific Officer. He received a Ph.D. in Chemistry at the University of California, Berkeley, as a Chevron Fellow in the lab of Professor Carolyn Bertozzi. His research included developing and applying Redwood’s platform technology to cell surface modifications. Prior to joining Professor Bertozzi’s lab, Dr. Rabuka worked at the Burnham Institute, synthesizing complex glycans, and then became an early employee of Optimer Pharmaceuticals, and focused on the development of glycan and macrolide based antibiotics. He graduated with a double honors bachelor’s in chemistry and biochemistry from the University of Saskatchewan where he received the Dean’s Science Award, and he holds a master’s in chemistry from the University of Alberta. Dr. Rabuka has authored more than 30 major publications, as well as numerous book chapters and patents.

For more information on the PEGS conference, visit Catalent/PEGS and to arrange a meeting with Dr. Rabuka at the event, contact Richard Kerns at NEPR - richard@nepr.eu

Media Contacts:

Chris Halling
+44 (0)7580 041073
chris.halling@catalent.com

Richard Kerns
+44 (0)161 728 5880
richard@nepr.eu

About SMARTag® Technology

Catalent’s proprietary SMARTag site-specific protein-modification and linker technologies were developed by Redwood Bioscience to enable the generation of homogenous bioconjugates engineered to enhance potency, safety and stability. The technology employs natural post-translational modifications found in human cells to create one or more aldehyde tags at designated sites on protein molecules. These chemical “handles’’ are then stably conjugated to payloads (e.g. cytotoxic or effector) to prevent their systemic release. The SMARTag platform provides precise payload positioning, stable, site-specific conjugation and defined stoichiometry of drug–protein ratios. The control afforded by the technology enables identification of superior drugs from libraries of differentially designed conjugates. Catalent acquired Redwood Bioscience in 2014. For more information on Catalent Biologics, visit www.catalentbiologics.com

About Catalent

Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 10,000 people, including over 1,400 scientists, at more than 30 facilities across five continents, and in fiscal 2016 generated $1.85 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com

More products. Better treatments. Reliably supplied.™